Buiten RA, Ploumen EH, Zocca P, et al. - Researchers evaluated the 2‐year clinical performance of three drug‐eluting stents in all‐comer patients having severely calcified coronary lesions. A total of 3,514 all‐comer patients were randomized to biodegradable polymer Synergy everolimus‐eluting stents (EES) or Orsiro sirolimus‐eluting stents (SES), vs durable polymer Resolute Integrity zotarolimus‐eluting stents (ZES), in the BIO‐RESORT trial. A post hoc analysis was performed examining 783 patients (22.3%) with at least one severely calcified target lesion. The occurrence of the main composite endpoint target vessel failure, at 2‐year follow‐up, was reported in 19/252 (7.6%) and 33/265 (12.6%) of the EES and ZES‐treated patients, respectively. In multivariate analysis, implantation of EES, but not SES, was found to be independently related to lower target vessel revascularization rates vs in ZES. Overall, a lower 2‐year target vessel revascularization rate was reported in relation to treatment with EES vs treatment with ZES in BIO‐RESORT participants with severely calcified target lesions.